Joint Transnational Call (JTC2018)

These projects were funded under E-Rare.

Factsheet (PDF)

General information
Topic: Transnational research projects onhypothesis-driven use of multi-omic integrated approaches for discovery of diseases causes and/or functional validation in the context of rare diseases.
Budget: 17 milion €
Funded projects: 13
The following funding organisations have decided to open the tenth E-Rare Joint Transnational Call (JTC 2018) for funding multilateral research projects on rare diseases:

  • Austrian Science Fund (FWF), Austria
  • Research Foundation Flanders (FWO), Belgium, Flanders
  • Fund for Scientific Research – FNRS (F.R.S.-FNRS), Belgium, French-speaking community
  • Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada
  • Fonds de recherche du Québec-Santé (FRQS), Québec (Canada)
  • Ministry of Education, Youth and Sports (MEYS), Czech Republic
  • Academy of Finland (AKA), Finland
  • French National Research Agency (ANR), France
  • Federal Ministry of Education and Research (BMBF), Germany
  • German Research Foundation (DFG), Germany
  • General Secretariat for Research and Technology (GSRT), Greece
  • National Research, Development and Innovation Office (NKFIH), Hungary
  • Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
  • Italian Ministry of Health (MoH-IT), Italy
  • State Education Development Agency (VIAA), Latvia
  • National Centre for Research and Development (NCBR), Poland
  • Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
  • National Institute of Health Carlos III (ISCIII), Spain
  • Swiss National Science Foundation (SNSF), Switzerland
  • Netherlands Organization for Health Research and Development (ZonMw), The Netherlands
  • The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey
  • ReCogntiON: Recognition and Validation of Druggable Targets from the Response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients fro
  • INTEGRALS: INTEGRative multi-OMICs approaches on iPSC-derived 2D and 3D models to elucidate the role of immune and energy metabolism related genes/pathways in Amyotrophic Lateral Sclerosis
  • MSA-Omics: Multi-omics approach to predict therapeutic targets for multiple system atrophy
  • IMPACT: Identification of converging Molecular Pathways Across Chromatinopathies as Targets for Therapy
  • RAinRARE: Integrated analyses of retinoic acid signaling to understand and treat rare form of progressive motor impairment
  • HETER-OMICS: Multi-OMICS interrogation of cerebral cortical malformations
  • EUROGLYCAN: Towards a new era for the identification and characterisation of inborn errors of glycosylation
  • NARCOMICS: Deciphering the immunopathogenesis of type 1 nacolepsy with omics
  • MAXOMOD: Multi-omic analysis of axono-synaptic degeneration in motoneuron disease
  • LADOMICS: Multi-omics approaches for discovery of new disease mechanisms of LAD-I and LAD-III immunodeficiencies
  • i-PAD: Integrative Multi-Omics Analysis of Primary Antibody Deficiency (PAD) Patients for Stratification
  • REPETOMICS: Genomic Instability of Expanded Repeats in HD and ALS/FTD
  • UltraAIE: Single cell-based ultra high-resolution characterization of intrathecal immunity in Autoimmune Encephalitis